Nunzia Pharmaceutical Stock Performance
| NUNZ Stock | USD 0 0.00 0.00% |
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Nunzia Pharmaceutical are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Nunzia Pharmaceutical has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Nunzia Pharmaceutical is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
Nunzia |
Nunzia Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 0.30 in Nunzia Pharmaceutical on August 25, 2024 and sell it today you would earn a total of 0.00 from holding Nunzia Pharmaceutical or generate 0.0% return on investment over 90 days. Nunzia Pharmaceutical is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Nunzia, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nunzia Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nunzia Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Nunzia Pharmaceutical, and traders can use it to determine the average amount a Nunzia Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| NUNZ |
Based on monthly moving average Nunzia Pharmaceutical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nunzia Pharmaceutical by adding Nunzia Pharmaceutical to a well-diversified portfolio.
Nunzia Pharmaceutical Fundamentals Growth
Nunzia Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Nunzia Pharmaceutical, and Nunzia Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nunzia Pink Sheet performance.
| Return On Asset | -2702.39 | |||
| Current Valuation | 87.59 M | |||
| Shares Outstanding | 434.52 M | |||
| EBITDA | (9.02 M) | |||
| Cash And Equivalents | 5.07 K | |||
| Total Debt | 139.96 K | |||
| Cash Flow From Operations | (86.78 K) | |||
| Earnings Per Share | (0.28) X | |||
| Total Asset | 5.13 K | |||
About Nunzia Pharmaceutical Performance
Evaluating Nunzia Pharmaceutical's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Nunzia Pharmaceutical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nunzia Pharmaceutical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company. Nunzia Pharmaceutical Company was incorporated in 1986 and is based in Long Beach, California. Nunzia Pharmaceutical is traded on OTC Exchange in the United States.Things to note about Nunzia Pharmaceutical performance evaluation
Checking the ongoing alerts about Nunzia Pharmaceutical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Nunzia Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nunzia Pharmaceutical generated a negative expected return over the last 90 days | |
| Nunzia Pharmaceutical has some characteristics of a very speculative penny stock | |
| Nunzia Pharmaceutical has high likelihood to experience some financial distress in the next 2 years | |
| Nunzia Pharmaceutical currently holds 139.96 K in liabilities. Nunzia Pharmaceutical has a current ratio of 0.2, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nunzia Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Nunzia Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nunzia Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nunzia to invest in growth at high rates of return. When we think about Nunzia Pharmaceutical's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (9.02 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nunzia Pharmaceutical currently holds about 5.07 K in cash with (86.78 K) of positive cash flow from operations. | |
| Roughly 82.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Nunzia Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nunzia Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Nunzia Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nunzia Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nunzia Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nunzia Pharmaceutical's pink sheet. These opinions can provide insight into Nunzia Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Nunzia Pink Sheet Analysis
When running Nunzia Pharmaceutical's price analysis, check to measure Nunzia Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nunzia Pharmaceutical is operating at the current time. Most of Nunzia Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Nunzia Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nunzia Pharmaceutical's price. Additionally, you may evaluate how the addition of Nunzia Pharmaceutical to your portfolios can decrease your overall portfolio volatility.